sennoside a&b has been researched along with Osteosarcoma in 1 studies
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YC | 1 |
| Chang, CN | 1 |
| Hsu, HC | 1 |
| Chiou, SJ | 1 |
| Lee, LT | 1 |
| Hseu, TH | 1 |
1 other study available for sennoside a&b and Osteosarcoma
| Article | Year |
|---|---|
Sennoside B inhibits PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells.
Topics: Anthraquinones; Becaplermin; Cathartics; Cell Line, Tumor; Cell Proliferation; Extracellular Signal- | 2009 |